Chronic cardiotoxicity of anticancer anthracyclines in the rat: Role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity

British Journal of Pharmacology

Volumn 139, Issue 3, 2003, Pages 641-651

  Sacco, Giuseppe ^a   Giampietro, Rossella ^b   Salvatorelli, Emanuela ^b   Menna, Pierantonio ^b   Bertani, Nicoletta ^c   Graiani, Gallia ^c   Animati, Fabio ^a   Goso, Cristina ^a   Maggi, Carlo A ^a   Manzini, Stefano ^a   Minotti, Giorgio ^b  

^a Menarini Ricerche SpA   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

Author keywords

Cardiotoxicity; Doxorubicin; Epirubicin; MEN 10755; Secondary alcohol metabolites

Indexed keywords

ACONITATE HYDRATASE; ANTHRACYCLINE ANTIBIOTIC AGENT; DOXORUBICIN; EPIRUBICIN; ISOPRENALINE; SABARUBICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMEGALY; CARDIOTOXICITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG METABOLISM; DRUG UPTAKE; ELECTROCARDIOGRAM; ENZYME INACTIVATION; HEMODYNAMIC PARAMETERS; HEMODYNAMICS; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; RAT;

EID: 10744224134     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705270     Document Type: Article

References (28)

1. ARCAMONE, F., ANIMATI, F., BERETTONI, M., BIGIONI, M., CAPRANICO, G., CASAZZA, A.M., CASERINI, C, CIPOLLONE, A., DE CESARE, M., FRANCIOTTI, M., LOMBARDI, P., MADAMI, A., MANZINI, S., MONTEAGUDO, E., POLIZZI, D., PRATESI, G., RIGHETTI, S.C., SALVATORE, C., SUPINO, R. & ZUNINO, F. (1997) Doxorubicin disaccharide analogue: apoptosis-related improvement of efficacy in vivo. J. Natl. Cancer Inst., 89, 1217 - 1223.
2. AX, W., SOLDAN, M., KOCH, L. & MASER, E. (2000) Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem. Pharmacol., 59, 293 - 300.
3. BERTAZZOLI, C., BELLINI, O., MAGRINI, U. & TOSANA, M.G. (1979) Quantitative experimental evaluation of adriamycin cardiotoxicity in the mouse. Cancer Treat. Rep., 63, 1877 - 1883.
4. CIRILLO, R., SACCO, G., VENTURELLA, S., BRIGHTWELL, J., GIACHETTI, A. & MANZINI, S. (2000) Comparison of doxorubicin- and MEN 10755-induced long term progressive cardiotoxicity in the rat. J. Cardiovasc. Pharmacol., 35, 100 - 108.
5. DANESI, R., DEL TACCA, M. & SOLDANI, G. (1986) Measurement of the SαT segment as the most reliable electrocardiogram parameter for the assessment of adriamycin-induced cardiotoxicity in the rat. J. Pharmacol. Methods., 16, 251 - 258.
6. DANESI, R., FOGLI, R., GENNARI, A., CONTE, P. & DEL TACCA, M. (2002) Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clin. Pharmacokinet., 41, 431 - 444
7. FORREST, G.L., AKMAN, S., DOROSHOW, J., RIVERA, H. & KAPLAN, W.D. (1991) Genomic sequence and expression of a cloned human carbonyl reductase gene with daunorubicin reductase activity. Mol. Pharmacol., 40, 502 - 507.
8. FORREST, G.L., GONZALEZ, B., TSENG, W., LI, X. & MANN, J. (2000) Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Cancer Res., 60, 5158 - 5164.
9. GERVASI, P.G., AGRILLO, M.R., CITTI, L., DANESI, R. & DEL TACCA, M. (1986) Superoxide anion production by adriamycinol from cardiac sarcosomes and by mitochondrial NADH dehydrogenase. Anticancer Res., 6, 1231 - 1235.
10. GONZALEZ, B., AKMAN, S., DOROSHOW, J., RIVERA, H., KAPLAN, W.D. & FORREST, G.L. (1995) Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells. Cancer Res., 55, 4646 - 4650.
11. GONZALEZ-PAZ, O., POLIZZI, D., DE CESARE, M., ZUNINO, F., BIGIONI, M., MAGGI, C.A., MANZINI, S. & PRATESI, G. (2001) Tissue distribution, antitumour activity and in vivo apoptosis induction by MEN 10755 in nude mice. Eur. J. Cancer, 37, 431 - 437.
12. KOTAMRAJU, S., CHITAMBAR, C.R., KALIVENDI, S.V., JOSEPH, J. & KALAYANARAMAN, B. (2002) Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells: role of oxidant-induced iron signaling in apoptosis. J. Biol. Chem., 277, 17179 - 17187.
13. MAESSEN, P.A., MROSS, K.B., PINEDO, H.M. & van dec VIJGH, WJ. (1987) Metabolism of epidoxorubicin in animals: absence of glucuronidation. Cancer. Chemother. Pharmacol., 20, 85 - 87.
14. MAZUÉ, G., IATROPOULOS, M., IMONDI, A., CASTELLINO, S., BRUGHERA, M., PODESTÁ, A., DELLA TORRE, P. & MONETA, D. (1995) Anthracyclines: a review of general and special toxicity. Int. J. Oncol., 7, 713 - 726.
15. MINOTTI, G., CAIRO, G. & MONTI, E. (1999) Role of iron in anthracycline cardiotoxicity: new tunes for an old song? FASEB J., 13, 199 - 212.
16. MINOTTI, G., CAVALIERE, A.F., MORDENTE, A., ROSSI, M., SCHIAVELLO, R., ZAMPARELLI, R. & POSSATI, G.F. (1995) Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. J. Clin. Invest., 95, 1595 - 1605.
17. MINOTTI, G., LICATA, S., SAPONIERO, A., MENNA, P., CALAFIORE, A.M., DI GIAMMARCO, G., LIBERI, G., ANIMATI, F., CIPOLLONE, A., MANZINI, S. & MAGGI, C.A. (2000) Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe - 4S] reactivity of its secondary alcohol metabolite. Chem. Res. Toxicol., 13, 1336 - 1341.
18. MINOTTI, G., PARLANI, M., SALVATORELLI, E., MENNA P., CIPOLLONE, A., ANIMATI, F., MAGGI, C.A. & MANZINI, S. (2001a) Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue. Br. J. Pharmacol., 134, 1271 - 1278.
19. MINOTTI, G., RONCHI, R., SALVATORELLI, E., MENNA, P. & CAIRO, G. (2001b) Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res., 61, 8422 - 8428.
20. MYERS, C. (1998) The role of iron in doxorubicin-induced cardiomyopathy. Semin. Oncol., 25 (Suppl. 10), 10 - 14.
21. NARAHARI, J., MA, R., WANG, M. & WALDEN, W.E. (2000) The aconitase function of iron regulatory protein 1. Genetic studies in yeast implicate its role in iron-mediated redox regulation. J. Biol. Chem., 275, 16227 - 16234.
22. OLSON, R.D. & MUSHLIN, P.S. (1990) Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J., 4, 3076 - 3086.
23. ROBERT, J. (1993) Epirubicin. Clinical pharmacology and dose - effect relationship. Drugs, 45 (Suppl. 2), 20 - 30.
24. SACCO, G., BIGIONI, M., EVANGELISTA, S., GOSO, C., MANZINI, S. & MAGGI, C.A. (2001) Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur. J. Pharmacol., 414, 71 - 78.
25. SINGAL, P.K. & ILISKOVIC, N. (1998) Doxorubicin-induced cardiomyopathy. N. Engl. J. Med., 339, 900 - 905.
26. STOSCHECK, C.M. (1990) Quantitation of protein. Methods Enzymol., 182, 50 - 68.
27. WANG, S., KOTAMRAJU, S., KONOREV, E, KALIVENDI, S., JOSEPH, J. & KALYANARAMAN, B. (2002) Activation of nuclear factor kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic - The role of hydrogen peroxide. Biochem. J., 367, 729 - 740.
28. +) handling and contractile function in rat heart. Br. J. Pharmacol., 131, 342 - 348.